David Cederberg

Lund, M 22185, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Evaluation of a Novel Automated Cerebral Ventricular Drainage System for Intracranial Pressure Monitoring and Cerebrospinal Fluid Drainage in Neurocritical Care Patients: A Prospective, Randomized Clinical Study.

Evaluation of a Novel Automated Cerebral Ventricular Drainage System for Intracranial Pressure Monitoring and Cerebrospinal Fluid Drainage in Neurocritical Care Patients: A Prospective, Randomized Clinical Study.

Journal: Neurocritical care

Published: September 01, 2025

Outcome in adult patients with severe TBI, using a management protocol allowing a cerebral perfusion pressure ≤ 60 mmHg - a retrospective study over 10 years.

Outcome in adult patients with severe TBI, using a management protocol allowing a cerebral perfusion pressure ≤ 60 mmHg - a retrospective study over 10 years.

Journal: Acta neurochirurgica

Published: May 15, 2025

Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial.

Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial.

Journal: Brain : a journal of neurology

Published: May 08, 2025

Altered Neurocritical Care Management of Patients with Severe Traumatic Brain Injury Following Changed Positions of the Zero-Reference Points for Intracranial and Arterial Pressure Measurement.

Altered Neurocritical Care Management of Patients with Severe Traumatic Brain Injury Following Changed Positions of the Zero-Reference Points for Intracranial and Arterial Pressure Measurement.

Journal: Neurocritical care

Published: May 07, 2025

Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models.

Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models.

Journal: Scientific reports

Published: February 13, 2025

Corrigendum to "Heparin-bindning protein as a marker of ventriculostomy related infection and central nervous system inflammation in neuro-intensive care" [Clin. Neurol. Neurosurg. 229 (2023) 107752].

Corrigendum to "Heparin-bindning protein as a marker of ventriculostomy related infection and central nervous system inflammation in neuro-intensive care" [Clin. Neurol. Neurosurg. 229 (2023) 107752].

Journal: Clinical neurology and neurosurgery

Published: July 11, 2024

Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial.

Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial.

Journal: Trials

Published: March 06, 2024

Antisecretory factor in severe traumatic brain injury (AFISTBI): protocol for an exploratory randomized placebo-controlled trial.

Antisecretory factor in severe traumatic brain injury (AFISTBI): protocol for an exploratory randomized placebo-controlled trial.

Journal: Trials

Published: December 19, 2023

Heparin-binding protein as a marker of ventriculostomy related infection and central nervous system inflammation in neuro-intensive care.

Heparin-binding protein as a marker of ventriculostomy related infection and central nervous system inflammation in neuro-intensive care.

Journal: Clinical neurology and neurosurgery

Published: December 12, 2022

Low Morbidity and Mortality in Children with Severe Traumatic Brain Injury Treated According to the Lund Concept: A Population-Based Study.

Low Morbidity and Mortality in Children with Severe Traumatic Brain Injury Treated According to the Lund Concept: A Population-Based Study.

Journal: Journal of neurotrauma

Published: December 06, 2022

Prolonged and intense neuroinflammation after severe traumatic brain injury assessed by cerebral microdialysis with 300 kDa membranes.

Prolonged and intense neuroinflammation after severe traumatic brain injury assessed by cerebral microdialysis with 300 kDa membranes.

Journal: Journal of neuroimmunology

Published: November 16, 2022

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.

Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.

Journal: BMC neurology

Published: September 19, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026